Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Prothena CEO Dale Schenck Dies From Pancreatic Cancer

Executive Summary

Prothena CEO Dale Schenk, the scientist behind innovative medicines that included bapineuzumab and Tysabri, died from pancreatic cancer on Sept. 30 – less than two years after he revealed his diagnosis.


Related Content

Lilly's Leap Tests Investors' Faith In Solanezumab
JPM Parting Shots: Milestones Ahead For Prothena, Sage, Aimmune, UniQure
Prothena reveals positive amyloidosis data; CEO's cancer
Roche in $600m deal for Parkinson's antibody program
From Tysabri to bapi and back to the drawing board: Dale Schenk speaks
Prothena spins out of Elan
Pfizer and partners pull plug on bapineuzumab for Alzheimer's after second Phase III failure


Related Companies